Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus

Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus

Breast cancer is the most frequently diagnosed cancer in the UAE and a leading cause of cancer-related mortality. Although early diagnosis contributes to favorable prognoses, novel treatment modalities like antibody-drug conjugates (ADCs) have significantly broadened the therapeutic landscape for pa...

Full description

Saved in:

Bibliographic Details
Main Authors:	Emad Dawoud, Fathi Azribi, Aref Chehal, Shaheenah Dawood, Syed Hammad Tirmazy, Dina Hamza, Hassan Jaafar, Hussam Marashi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Oncology
Subjects:	HER2 metastatic breast cancer trastuzumab deruxtecan T-DXd targeted therapy antibody-drug conjugates
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1443962/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer
by: Jonathan Henricks, et al.
Published: (2025-02-01)

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre
by: Anna-Maria Lazaratos, et al.
Published: (2024-12-01)

Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan
by: Ünal Metin Tokat, et al.
Published: (2025-01-01)

Response to trastuzumab deruxtecan and delayed immune-related events in a patient with metastatic HER2-positive NSCLC: a case report and literature review
by: Lu Wang, et al.
Published: (2025-01-01)

Deep learning-based prediction of HER2 status and trastuzumab treatment efficacy of gastric adenocarcinoma based on morphological features
by: Zhida Wu, et al.
Published: (2025-01-01)

A versatile gold leaf immunosensor with a novel surface functionalization strategy based on protein L and trastuzumab for HER2 detection
by: Ivana Kundacina, et al.
Published: (2025-01-01)

Induction of SUSD2 by STAT3 Activation Is Associated with Tumor Recurrence in HER2-Positive Breast Cancer
by: Yisun Jeong, et al.
Published: (2024-12-01)

Investigation of <i>ITGB3</i> Heterogeneity to Overcome Trastuzumab Resistance in HER2-Positive Breast Cancer
by: Asiye Busra Boz Er
Published: (2024-12-01)

Quercetin inhibits truncated isoform of dopamine- and cAMP-regulated phosphoprotein as adjuvant treatment for trastuzumab therapy resistance in HER2-positive breast cancer
by: Han-Sheng Chang, et al.
Published: (2024-09-01)

Update on Pulmonary Toxicity Induced by New Breast Cancer Treatments
by: Belluzzi L, et al.
Published: (2025-01-01)

A Cost-Effective and Robust Cell-Based Bioassay Method for Evaluating the Bioactivity of Trastuzumab-like Antibodies
by: Pooja Bharali, et al.
Published: (2024-12-01)

Fluorescence Lifetime Imaging for Quantification of Targeted Drug Delivery in Varying Tumor Microenvironments
by: Amit Verma, et al.
Published: (2025-01-01)

Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo
by: Zheng Wang, et al.
Published: (2024-12-01)

Impact of adjuvant trastuzumab therapy and its discontinuation on cardiac function and mortality in patients with early-stage breast cancer: An analysis based on the Japanese Receipt Claim Database
by: Keiko Miyazato, et al.
Published: (2025-02-01)

Prognosis and cardiotoxicity associated to adjuvant trastuzumab for breast cancer: real world study in a public health system
by: Ana Elisa Ribeiro da Silva Cabello, et al.
Published: (2025-01-01)

Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer
by: Hanghang Ma, et al.
Published: (2025-02-01)

Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan
by: Alessandra Fabi, et al.
Published: (2025-01-01)

A phase Ia study of a novel anti-HER2 antibody–drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors
by: Chenfei Zhou, et al.
Published: (2025-01-01)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
by: Satomi Watanabe, et al.
Published: (2019-03-01)

Development of prognostic models for HER2-positive metastatic breast cancer in females: a retrospective population-based study
by: Yan Chen, et al.
Published: (2024-12-01)

Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab to chemotherapy plus trastuzumab as neoadjuvant therapy
by: Huanhuan Li, et al.
Published: (2025-02-01)

CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2 − metastatic breast cancer
by: Susan Dent, et al.
Published: (2025-01-01)

Systematic Review and Network Meta-Analysis on Treating Hormone Receptor-Positive Metastatic Breast Cancer After CDK4/6 Inhibitors
by: Neha Pathak, et al.
Published: (2025-01-01)

HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
by: Salvatore Siena, et al.
Published: (2024-11-01)

Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy
by: Yan Zhang, et al.
Published: (2025-12-01)

Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
by: Salvatore Siena, et al.
Published: (2025-01-01)

Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report
by: Oliver Illini, et al.
Published: (2024-01-01)

An incidental diagnosis of an unusually located echinococcus alveolaris
by: Ganime Çoban, et al.
Published: (2024-12-01)

Serendipitous Diagnosis of Adenocarcinoma of the Mandible Metastasized from the Prostate: A Case Report
by: Krishna Satpathy, et al.
Published: (2024-12-01)

Iterative methods for solving fractional differential equations using non-polynomial splines
by: Faraidun K. Hamasalh, et al.
Published: (2024-12-01)

Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort
by: Hilin Yildirim, et al.
Published: (2025-02-01)

Recognition of HER2 expression in hepatocellular carcinoma and its significance in postoperative tumor recurrence
by: Ji‐Hua Shi, et al.
Published: (2019-03-01)

Gear Tooth Profile Design and Simulation based on Graphic Envelope Method
by: Xu Long
Published: (2016-01-01)

Stroke associated with microvascular tumoral infiltration in a patient with metastatic breast cancer
by: Joshua Mangerel, MD, et al.
Published: (2025-03-01)

CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer
by: Lorenzo Castagnoli, et al.
Published: (2025-01-01)

Enhancing electrocatalytic performance of RuO2-based catalysts: mechanistic insights, strategic approaches, and recent advances
by: Binod Raj KC, et al.
Published: (2025-01-01)

LRP1 involvement in FHIT-regulated HER2 signaling in non-small cell lung cancer
by: Théophile Ponchel, et al.
Published: (2025-03-01)

Roselyne et Roselon
by: Julie Sorel
Published: (2019-07-01)

Exploring the Anticancer Potential of MonoHER (7-Mono-O-(β-Hydroxyethyl)-Rutoside): Mitochondrial-Dependent Apoptosis in HepG2 Cells
by: Chujie Li, et al.
Published: (2025-01-01)

Synthesis, Structure, and Electrophysical and Electrochemical Properties of Novel Composite La<sub>0.9</sub>MnO<sub>3</sub>-LaFeO<sub>3</sub>
by: Mukhametkali Mataev, et al.
Published: (2024-12-01)